Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED HydrALAZINE Hydrochloride Tablets, USP: 10 mg - Orange, round, unscored tablets debossed with 'H' on one side and '38' on the other side in bottles of 100 (NDC code: 31722-519-01), 500 (NDC code: 31722-519-05), and 1000 (NDC code: 31722-519-10). 25 mg - Orange, round, unscored tablets debossed with 'H' on one side and '39' on the other side in bottles of 100 (NDC code: 31722-520-01), 500 (NDC code: 31722-520-05), and 1000 (NDC code: 31722-520-10). 50 mg - Orange, round, unscored tablets debossed with 'H' on one side and '40' on the other side in bottles of 100 (NDC code: 31722-521-01), 500 (NDC code: 31722-521-05), and 1000 (NDC code: 31722-521-10). 100 mg - Orange, round, unscored tablets debossed with 'H' on one side and '41' on the other side in bottles of 100 (NDC code: 31722-522-01) and 500 (NDC code: 31722-522-05). Dispense in a tight, light-resistant container as defined in the USP. Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. For more information, call 1-866-495-1995 Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: HETERO TM Hetero Labs Limited Jeedimetla, Hyderabad - 500 055, India OR By: Annora Pharma Pvt. Ltd. Sangareddy - 502313, Telangana, India OR By: HETERO TM Plot No. 28P1 to 36P1 & 37 to 54, Vemagal Industrial Area, Hobli Vemagal, Kolar, Karnataka - 563102, India. Revised: 02/2025 hydralazinecamberlogo; PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 10 mg 100s 25 mg 100s 50mg 100s 100 mg 100s hydralazine10mglabelhetero hydralazine10mglabelannora. hydralazine10mglabel hydralazine25mglabelhetero hydralazine25mglabelannora hydralazine25mglabel hydralazine50mglabelhetero hydralazine50mglabelannora hydralazine50mglabel hydralazine100mglabelhetero hydralazine100mglabelannora hydralazine100mglabel
- HOW SUPPLIED HydrALAZINE Hydrochloride Tablets, USP: 10 mg - Orange, round, unscored tablets debossed with 'H' on one side and '38' on the other side in bottles of 100 (NDC code: 31722-519-01), 500 (NDC code: 31722-519-05), and 1000 (NDC code: 31722-519-10). 25 mg - Orange, round, unscored tablets debossed with 'H' on one side and '39' on the other side in bottles of 100 (NDC code: 31722-520-01), 500 (NDC code: 31722-520-05), and 1000 (NDC code: 31722-520-10). 50 mg - Orange, round, unscored tablets debossed with 'H' on one side and '40' on the other side in bottles of 100 (NDC code: 31722-521-01), 500 (NDC code: 31722-521-05), and 1000 (NDC code: 31722-521-10). 100 mg - Orange, round, unscored tablets debossed with 'H' on one side and '41' on the other side in bottles of 100 (NDC code: 31722-522-01) and 500 (NDC code: 31722-522-05). Dispense in a tight, light-resistant container as defined in the USP. Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. For more information, call 1-866-495-1995 Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: HETERO TM Hetero Labs Limited Jeedimetla, Hyderabad - 500 055, India OR By: Annora Pharma Pvt. Ltd. Sangareddy - 502313, Telangana, India OR By: HETERO TM Plot No. 28P1 to 36P1 & 37 to 54, Vemagal Industrial Area, Hobli Vemagal, Kolar, Karnataka - 563102, India. Revised: 02/2025 hydralazinecamberlogo
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 10 mg 100s 25 mg 100s 50mg 100s 100 mg 100s hydralazine10mglabelhetero hydralazine10mglabelannora. hydralazine10mglabel hydralazine25mglabelhetero hydralazine25mglabelannora hydralazine25mglabel hydralazine50mglabelhetero hydralazine50mglabelannora hydralazine50mglabel hydralazine100mglabelhetero hydralazine100mglabelannora hydralazine100mglabel
Overview
HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1 -hydrazinophthalazine monohydrochloride, and its structural formula is: HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275 o C, with decomposition, and has a molecular weight of 196.64. Each tablet for oral administration contains 10 mg, 25 mg, 50 mg or 100 mg hydrALAZINE hydrochloride, USP. Tablets also contain anhydrous lactose, microcrystalline cellulose, sodium starch glycolate, stearic acid and FD&C Yellow # 6. hydralazinechemicalstructure
Indications & Usage
Essential hypertension, alone or as an adjunct.
Dosage & Administration
Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels. The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of hydrALAZINE. In a few resistant patients, up to 300 mg of hydrALAZINE daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of hydrALAZINE combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.
Warnings & Precautions
WARNINGS In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS, Laboratory Tests.)
Contraindications
Hypersensitivity to hydrALAZINE; coronary artery disease; mitral valvular rheumatic heart disease.
Adverse Reactions
Adverse reactions with hydrALAZINE are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency. Common: Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris Less Frequent: Digestive: constipation, paralytic ileus. o Cardiovascular: hypotension, paradoxical pressor response, edema. o Respiratory: dyspnea o Neurologic: peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety. o Genitourinary: difficulty in urination o Hematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly. o Hypersensitivity Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis. o Other: nasal congestion, flushing, lacrimation, conjunctivitis.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.